Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There was a post at one time showing micromatty had a reward posted for his head(lying) from another company.
Congrats brent, I should have asked you for advice. I bought 10000 more SLJB at 13 :). Other than those all of my remaining shares are at .07 however.
Someone tell Petar to present SLJB to investors in Dubai. This stock was presented today and gained over 7%.
VANCOUVER, BRITISH COLUMBIA, Oct 31, 2006 (MARKET WIRE via COMTEX) -- Taseko Mines Limited ("Taseko" or the "Company") (TKO) (TGB) will be presenting at the upcoming World Mining Metals/Oil & Gas Congress being held October 31 - November 2, 2006 in Dubai, UAE. Mr. Russell Hallbauer, Taseko's President and Chief Executive Officer, will speak to investors on Tuesday, October 31, 2006 at approximately 10:10 pm Pacific Time (1:10 am Eastern Time).
"just trying to point out how ridiculous some of u sound ;P"
about 95% of posts here-completely useless!
So, sortagreen-are you going to adopt a terrorist?
I agree midas-getting as bad as RB with all the BS posts!
Profiling? So What? From a pilot's point of view...
This is the most profound, most insightful message to Muslims I've seen. I think it should be read on Fox, sent to the President, and forwarded to any other form of media to express what so many of us feel toward the Muslims!
The paper stated today that some Muslim doctor is saying we are profiling him because he has been checked three times while getting on an airplane.
(A Letter From An American Airlines Pilot) This well spoken man, who is a pilot with American Airlines, says what is in his heart beautifully....read, absorb and pass on....it's time to get answers from those who claim their terrorist members do not represent them..why are their leaders not LOUDLY AND FIERCELY AND CONTINUOUSLY condemning their visible murderous brethren.
YOU WORRY ME!
By American Airlines Pilot - Captain John Maniscalco "I've been trying to say this since 9-11 but you worry me. I wish you didn't. I wish when I walked down the streets of this country that I love, that your color and culture still blended with the beautiful human landscape we enjoy in this country. But you don't blend in anymore. I notice you, and it worries me.
I notice you because I can't help it anymore. People from your homelands, professing to be Muslims, have been attacking and killing my fellow citizens and our friends for more than 20 years now. I don't fully understand their grievances and hate but I know that nothing can justify the inhumanity of their attacks.
On September 11, nineteen ARAB-MUSLIMS hijacked four jetliners in my country. They cut the throats of women in front of children and brutally stabbed to death others. They took control of those planes and crashed them into buildings killing thousands of proud fathers, loving sons, wise grandparents, elegant daughters, best friends, favorite coaches, fearless public servants, and children's mothers.
The Palestinians Celebrated, The Iraqis were overjoyed as was most of the Arab world. So I notice you now. I don't want to be worried. I don't want to be consumed by the same rage and hate and prejudice that has destroyed the soul of these terrorists. But I need your help. As a rational American, trying to protect my country and family in an irrational and unsafe world, I must know how to tell the difference between you, and the Arab/Muslim terrorist.
How do I differentiate between the true Arab/Muslim-Americans and the Arab/Muslims in our communities who are attending our schools, enjoying our parks, and living in OUR communities under the protection of OUR constitution, while they plot the next attack that will slaughter these same good neighbors and children? The events of September 11th changed the answer. It is not my responsibility to determine which of you embraces our great country, with ALL of its religions, with ALL of its different citizens, with all of its faults. It is time for every Arab/Muslim in this country to determine it for me.
I want to know, I demand to know, and I have a right to know whether or not you love America . Do you pledge allegiance to its flag? Do you proudly display it in front of your house, or on your car?
Do you pray in your many daily prayers that Allah will bless this nation, that He will protect and prosper it? Or do you pray that Allah with destroy it in one of your "Jihads"? Are you thankful for the freedom that only this nation affords? A freedom that was paid for by the blood of hundreds of thousands of patriots who gave their lives for this country? Are you willing to preserve this freedom by paying the ultimate sacrifice? Do you love America ? If this is your commitment, then I need YOU to start letting ME know about it.
Your Muslim leaders in this nation should be flooding the media at this time with hard facts on your faith, and what hard actions you are taking as a community and as a religion to protect the United States of America . Please, no more benign overtures of regret for the death of the innocent because I worry about who you regard as innocent. No more benign overtures of condemnation for the unprovoked attacks because I worry about what is unprovoked to you. I am not interested in any more sympathy...I am only interested in action. What will you do for America - our great country -- at this time of crisis, at this time of war?
I want to see Arab-Muslims waving the AMERICAN flag in the streets. I want to hear you chanting "Allah Bless America " I want to see young Arab/Muslim men enlisting in the military. I want to see a commitment of money, time, and emotion to the victims of this butchering and to this nation as a whole. The FBI has a list of over 400 people they want to talk to regarding the WTC attack. Many of these people live and socialize in Muslim communities. You know them. You know where they are. Hand them over to us, now! But I have seen little even approaching this sort of action. Instead I have seen an already closed and secretive community close even tighter. You have disappeared from the streets. You have posted armed security guards at your facilities. You have threatened lawsuits. You have screamed for protection from reprisals.
The very few Arab/Muslim representatives that HAVE appeared in the media were defensive and equivocating. They seemed more concerned with making sure that the United States proves who was responsible before taking action. They seemed more concerned with protecting their fellow Muslims from violence directed towards them in the United States and abroad than they did with supporting our country and denouncing "leaders" like Khadafi, Hussein, Farrakhan, and Arafat.
If the true teachings of Islam proclaim tolerance and peace and love for all people then I want chapter and verse from the Koran and statements from popular Muslim leaders to back it up. What good is it if the teachings in the Koran are good and pure and true when your "leaders" are teaching fanatical interpretations, terrorism, and intolerance?
It matters little how good Islam SHOULD BE if large numbers of the world's Muslims interpret the teachings of Mohammed incorrectly and adhere to a degenerative form of the religion. A form that has been demonstrated to us over and over again. A form whose structure is built upon a foundation of violence, death, and suicide. A form whose members are recruited from the prisons around the world. A form whose members (some as young as five years old) are seen day after day, week in and week out, year after year, marching in the streets around the world, burning effigies of our presidents, burning the American flag, shooting weapons into the air. A form whose members convert from a peaceful religion, only to take up arms against the great United States of America, the country of their birth. A form whose rules are so twisted, that their traveling members refuse to show their faces at airport security checkpoints, in the name of Islam.
Do you and your fellow Muslims hate us because our women proudly show their faces in public rather than cover up like a shameful whore? Do you and your fellow Muslims hate us because we drink wine with dinner, or celebrate Christmas? Do you and you fellow Muslims hate us because we have befriended Israel , the ONLY FRIENDLY CIVILIZED SOCIETY in the Muslim/Arab area, that thinks and acts like most Americans.
And if you and your fellow Muslims hate us, then why in the world are you even here? Are you here to take our money? Are you here to undermine our peace and stability? Are you here to destroy us? If so, I want you to leave. I want you to go back to your desert sandpit where women are treated like rats and dogs. I want you to take your religion, your friends, and your family back to your Islamic extremists, and STAY THERE! We will NEVER give in to your influence, your retarded mentality, your twisted, violent, intolerant religion.
We will NEVER allow the attacks of September 11, or any others for that matter, to take away that which is so precious to us: Our rights under the greatest constitution in the world. I want to know where every Arab/ Muslim in this country stands and I think it is my right and the right of every true citizen of this country to demand it. A right paid for by the blood of thousands of my brothers and sisters who died protecting the very institution that is protecting you and your family. I am pleading with you to let me know. I want you here as my brother, my neighbor, my friend, as a fellow American. But there can be no gray areas or ambivalence regarding your allegiance and it is up to YOU, to show ME, where YOU stand." "Until then .. you worry me." *********************************************************************************
News alert for Mondays Red Herring magazine-
Google News Alert for: Biophan
Magazine Preview: Is Google Still Hot?
Red Herring - CA,USA
... get an MRI. Learn how startup Biophan wants to make sure everyone can get an MRI in “Next Wave: Magnetic Defense.â€. For the complete ...
The federal securities laws prohibit the manipulation of securities. Specifically, manipulation is intentional conduct designed to deceive investors by controlling or artificially affecting the market for a security. Manipulation can involve a number of techniques to affect the supply of, or demand for, a stock. They include: spreading false or misleading information about a company; improperly limiting the number of publicly-available shares; or rigging quotes, prices or trades to create a false or deceptive picture of the demand for a security.
While the First Amendment protects freedom of speech, a charge of slander may be brought against someone who knowingly makes a false statement. Pleaes note that this is a civil matter, not a matter under the federal securities laws.
If you want to provide us specific details of persons being paid to bash a company, we would appreciate your letting us know. You can do this by filing a complaint at http://www.sec.gov/complaint.shtml.
Sincerely,
ROBERT T GREENE
U.S. Securities and Exchange Commission
(202)942-7221
Re: CVM and H & N cancer-from Yahoo board.
HPV linked to Head and Neck cancer (Not rated) 25-Oct-06 10:00 pm View all Topics | View all Messages < Newer Topic | Older Topic >
HPV tied to head & neck cancers (Not rated) 20-Oct-06 05:58 pm In 1998 John Hopkins Research Unit found that the virus HPV, human papilloma virus, was associated with many head and neck cancers via the PCR test. This was the same year that the HPV was associated with 98% of all cervical cancers by clinical trials using the PCR test. The latest evidence confirms that many head and neck cancers are due to hpv. In the case of the nasal cavity, the hpv may not be acting alone but with Epstein-Barr. With recent evidence that no cases of nasal cavity cancer is associated to tobacco use points to the importance for the need for an HPV vaccine. HPV induced cancers are now being taught in dental university schools. In UCLA, they expect in excess of 8,000 oral cavity cancers due to HPV this year. In the mouth, HPV may appear as cotton cancy under the tongue. The removal or partial removal of the tongue is the only method of treatment. Although many cancer areas of the body have reported a decline in numbers, this does not hold true for lip cancer. This cancer associated with HPV, may in terms of percentage growth be the largest gainers of any cancer on the body. Tonsil cancer is almost entirely 100% HPV. As for the pharnyx and larnyx cancer, these cancers are often associated with HPV. Next time you see a voice box for those that have had their voice box removed or visually see a plastic nose replacement for a nose removed---it could be due to HPV. As for brain tumors, HPV is sometimes present in tumors found in children of less than three years of age. Sometimes, hpv brain tumors are found in order people. As for the esophageus cancers, the Americans scientists say they have found HPV, but the Japanese medical community reports that they have not found HPV. The little purple pill advertized on tv is no match for HPV. The good news is that a new medicine called texotere has been approved by the FDA for head and neck cancers-squamous cell- is good news.
By the way, in 1998 when John Hopkins discovered that many of the same strains that are associated with genital HPV infections are associated with head and neck cancers, this may have been the turning point from names to numbers for HPV strains. This was also the same year that the medical community reported that more women were being reported to be infected by sexual contact for the HIV than any other means-blood or drugs. Now that we know that HIV is difficult to transmit by sexual contact unless a std is present, most notably HPV, the medical community now knows that a vaccine for HPV will go a long way to limit the spread of HIV/AIDS.
Last year was the first year that cancer deaths exceeded cardiovascular. In the past, surgeries for cancer removal kept the number of cancer deaths in check. However, the large increase especially for older Americans due to cancer deaths exceeded cardiovascular. Cervical Cancer is the 7th leading cancer for women over 50. However, a look at the many other cancers now associated with HPV, makes the number larger. With one in seven women reporting breast cancer and one in four having an hysterectomy, the need to focus on cancer is urgent. HPV is associated with less than 10% of the breast cancer and is not the major factor for hysterectomies-fibroids are- but an HPV vaccine will go a long way toward a major change in the life of many Americans. The disfigurements of head and cancer victims to those that have experience hysterectomies due to this deadly virus HPV. Let's hope that Glaxo and Merck put those plastic nose makers and voice box makers out of business with their new vaccine for HPV.
Fog-looks like you pulled his string,lol.
No bloodhound, you did not miss it! You failed to answer this post truthfully so therefore you are the epitome of deceitful message board posters.
Posted by: Stockbuilder
In reply to: bloodhound99 who wrote msg# 1965 Date:10/22/2006 12:21:03 PM
Post #of 2026
"Why do I ask"? Well # 1 reason is posters bash 24/7 without owning a stock they are either;
1-paid by someone to do so
2-have a hidden agenda
3-been fired by the company
4-are attempting to manipulate stock down
5-are a lying pos just doing it for fun
6-have no friends or family
7-all of the above
Which are you?
newgreen, I also proved him a liar in my previous posts (to him).
"Fact is nothing new is coming from anyone, it is all re-hash about when the promise was made, and pronostication as to when the A/F's will come out.
Maybe shutting it down is the wrong approach, how about a boycott of the board by all the true investors and believers and let the kids talk amoung themselves"
I totally agree-hundreds of posts every day and 95% completely useless!
CVM is a speculative buy IMO, because they already have Canadian FDA ok for PIII trials but have been waiting forever on U.S. permission. If you want to take a chance, remember biotech investing is not for the weak.
October 24, 2006 12:15 PM Eastern Time
Dutton Associates Announces Investment Opinion: CEL-SCI Speculative Buy Rating in Initiating Coverage by Dutton Associates
NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates coverage of CEL-SCI (AMEX:CVM) with a speculative buy rating and a $1.00 target price. The 15-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. CEL-SCI Corporation is preparing for a multi-country, multi-center, 500 patient, pivotal phase III trial with Multikine®, the Company’s unique, proprietary product intended as adjunctive, first-line therapy for squamous cell carcinoma of the head and neck (SCCHN), a disease whose recurrence rate is common and prognosis remains poor despite the addition of both radiation and chemotherapy to surgery. We believe the results of this study will dictate the success or failure of CEL-SCI as an investment. The clinical use of Multikine in over 200 patients to date suggests the product is safe and potentially efficacious. We believe Multikine is possibly a first in a class of drugs that acts on both the cancer and the host’s anti-cancer immune response. We believe Multikine will eventually take its rightful place as part of the armamentarium for the treatment of SCCHN. We believe the value of the common stock of CEL-SCI could be multiples of its current market capitalization of approximately $54 million if Multikine proves successful in its upcoming clinical trial and considering the drug will participate in a multiple-billion dollar market for the treatment of SCCHN.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 10/24/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
Contacts
Dutton Associates
John M. Dutton, President, 916-941-8119
At A Glance
October 24, 2006 12:15 PM Eastern Time
Dutton Associates Announces Investment Opinion: CEL-SCI Speculative Buy Rating in Initiating Coverage by Dutton Associates
NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates coverage of CEL-SCI (AMEX:CVM) with a speculative buy rating and a $1.00 target price. The 15-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. CEL-SCI Corporation is preparing for a multi-country, multi-center, 500 patient, pivotal phase III trial with Multikine®, the Company’s unique, proprietary product intended as adjunctive, first-line therapy for squamous cell carcinoma of the head and neck (SCCHN), a disease whose recurrence rate is common and prognosis remains poor despite the addition of both radiation and chemotherapy to surgery. We believe the results of this study will dictate the success or failure of CEL-SCI as an investment. The clinical use of Multikine in over 200 patients to date suggests the product is safe and potentially efficacious. We believe Multikine is possibly a first in a class of drugs that acts on both the cancer and the host’s anti-cancer immune response. We believe Multikine will eventually take its rightful place as part of the armamentarium for the treatment of SCCHN. We believe the value of the common stock of CEL-SCI could be multiples of its current market capitalization of approximately $54 million if Multikine proves successful in its upcoming clinical trial and considering the drug will participate in a multiple-billion dollar market for the treatment of SCCHN.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 10/24/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
Contacts
Dutton Associates
John M. Dutton, President, 916-941-8119
At A Glance
October 24, 2006 12:15 PM Eastern Time
Dutton Associates Announces Investment Opinion: CEL-SCI Speculative Buy Rating in Initiating Coverage by Dutton Associates
NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates coverage of CEL-SCI (AMEX:CVM) with a speculative buy rating and a $1.00 target price. The 15-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. CEL-SCI Corporation is preparing for a multi-country, multi-center, 500 patient, pivotal phase III trial with Multikine®, the Company’s unique, proprietary product intended as adjunctive, first-line therapy for squamous cell carcinoma of the head and neck (SCCHN), a disease whose recurrence rate is common and prognosis remains poor despite the addition of both radiation and chemotherapy to surgery. We believe the results of this study will dictate the success or failure of CEL-SCI as an investment. The clinical use of Multikine in over 200 patients to date suggests the product is safe and potentially efficacious. We believe Multikine is possibly a first in a class of drugs that acts on both the cancer and the host’s anti-cancer immune response. We believe Multikine will eventually take its rightful place as part of the armamentarium for the treatment of SCCHN. We believe the value of the common stock of CEL-SCI could be multiples of its current market capitalization of approximately $54 million if Multikine proves successful in its upcoming clinical trial and considering the drug will participate in a multiple-billion dollar market for the treatment of SCCHN.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 10/24/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
Contacts
Dutton Associates
John M. Dutton, President, 916-941-8119
At A Glance
October 24, 2006 12:15 PM Eastern Time
Dutton Associates Announces Investment Opinion: CEL-SCI Speculative Buy Rating in Initiating Coverage by Dutton Associates
NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates coverage of CEL-SCI (AMEX:CVM) with a speculative buy rating and a $1.00 target price. The 15-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. CEL-SCI Corporation is preparing for a multi-country, multi-center, 500 patient, pivotal phase III trial with Multikine®, the Company’s unique, proprietary product intended as adjunctive, first-line therapy for squamous cell carcinoma of the head and neck (SCCHN), a disease whose recurrence rate is common and prognosis remains poor despite the addition of both radiation and chemotherapy to surgery. We believe the results of this study will dictate the success or failure of CEL-SCI as an investment. The clinical use of Multikine in over 200 patients to date suggests the product is safe and potentially efficacious. We believe Multikine is possibly a first in a class of drugs that acts on both the cancer and the host’s anti-cancer immune response. We believe Multikine will eventually take its rightful place as part of the armamentarium for the treatment of SCCHN. We believe the value of the common stock of CEL-SCI could be multiples of its current market capitalization of approximately $54 million if Multikine proves successful in its upcoming clinical trial and considering the drug will participate in a multiple-billion dollar market for the treatment of SCCHN.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 10/24/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
Contacts
Dutton Associates
John M. Dutton, President, 916-941-8119
At A Glance
Thanks trendy-will do. I love to report scam artists to SEC.
"Why do I ask"? Well # 1 reason is posters bash 24/7 without owning a stock they are either;
1-paid by someone to do so
2-have a hidden agenda
3-been fired by the company
4-are attempting to manipulate stock down
5-are a lying pos just doing it for fun
6-have no friends or family
7-all of the above
Which are you?
Great Brent! I was away from house all afternoon and just came back. When I left at 2 I said "just another week of waiting-wasted",lol. Now, how long will it take Petar to read it :)?
AllCommonSense; as you have refused to reply to my THIRD request to come clean on your "investment (?)" here I will have to assume you are indeed a paid scam artist. At the very least I am 100% sure you have a hidden agenda.
Perhaps you will answer this question. Were you ever fired by NNVC or one of the officers of company?
As others have done, I will report you to IH admin. and also SEC for attempted stock manipulation!
bloodhound;do you own this stock?
Ok, fess up. Who broke their piggy bank and bought 200s at.0095?
(Thats two hundred ;))
PRZ (Paincare)now up 26% for day on news.
AllCommonSense, THIRD request. Do you own,or have you ever owned NNVC stock? If you do not answer I will assume you are paid by a hedge fund or you are a scam artist OR BOTH!!!!
Up 22% on this news-
PainCare Holdings Unveils Financial Restructuring Plan
By PR Newswire
Last Update: 10/19/2006 8:30:00 AM Data provided by
ORLANDO, Fla., Oct 19, 2006 /PRNewswire-FirstCall via COMTEX/ -- PainCare Holdings, Inc. (PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today unveiled its financial restructuring plan providing for the sale of the Company's interests in its ambulatory surgery centers (ASCs). The proceeds of the proposed sale(s) are expected to yield PainCare sufficient cash to materially reduce or retire in full the Company's prevailing debt obligations, thus strengthening its balance sheet and financial position.
Randy Lubinsky, Chief Executive Officer of PainCare, stated, "Following extensive review of PainCare's available financing alternatives, including debt renegotiation and private and public equity raises, we determined that it was in the best interest of our Company and our shareholders to pursue a more creative and non-dilutive means to eliminate liquidity issues and access necessary growth capital."
Continuing, Lubinsky said, "Although the operation of our ASCs has proven to be complementary to PainCare's overall business platform, it is not central to PainCare's core mission. Recognizing that our surgery centers were valuable properties of interest to those companies who are actively engaged in consolidating assets within the ambulatory surgery center market, the sale of our ASCs became a logical and prudent solution to address the restructuring of our balance sheet, while also enhancing our cash position."
PainCare has engaged The Bloom Organization, a New Jersey-based investment banking firm with expertise in the sale and acquisition of ambulatory surgery centers. "The Bloom Organization is ideally suited to represent PainCare in the sale of our ASCs and has identified several serious suitors. With a goal of concluding negotiations and closing on these divestitures before year-end, PainCare plans to sizably reduce or pay off our debt obligations," stated Mark Szporka, Chief Financial Officer of PainCare.
"Proceeds from the sale(s) will also be used to finance certain growth opportunities, including select acquisitions, as they present themselves, and new business expansion initiatives currently in development," concluded Szporka.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management.
PRZ up 22% on news-
PainCare Holdings Unveils Financial Restructuring Plan
By PR Newswire
Last Update: 10/19/2006 8:30:00 AM Data provided by
ORLANDO, Fla., Oct 19, 2006 /PRNewswire-FirstCall via COMTEX/ -- PainCare Holdings, Inc. (PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today unveiled its financial restructuring plan providing for the sale of the Company's interests in its ambulatory surgery centers (ASCs). The proceeds of the proposed sale(s) are expected to yield PainCare sufficient cash to materially reduce or retire in full the Company's prevailing debt obligations, thus strengthening its balance sheet and financial position.
Randy Lubinsky, Chief Executive Officer of PainCare, stated, "Following extensive review of PainCare's available financing alternatives, including debt renegotiation and private and public equity raises, we determined that it was in the best interest of our Company and our shareholders to pursue a more creative and non-dilutive means to eliminate liquidity issues and access necessary growth capital."
Continuing, Lubinsky said, "Although the operation of our ASCs has proven to be complementary to PainCare's overall business platform, it is not central to PainCare's core mission. Recognizing that our surgery centers were valuable properties of interest to those companies who are actively engaged in consolidating assets within the ambulatory surgery center market, the sale of our ASCs became a logical and prudent solution to address the restructuring of our balance sheet, while also enhancing our cash position."
PainCare has engaged The Bloom Organization, a New Jersey-based investment banking firm with expertise in the sale and acquisition of ambulatory surgery centers. "The Bloom Organization is ideally suited to represent PainCare in the sale of our ASCs and has identified several serious suitors. With a goal of concluding negotiations and closing on these divestitures before year-end, PainCare plans to sizably reduce or pay off our debt obligations," stated Mark Szporka, Chief Financial Officer of PainCare.
"Proceeds from the sale(s) will also be used to finance certain growth opportunities, including select acquisitions, as they present themselves, and new business expansion initiatives currently in development," concluded Szporka.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management.
AllCommonSense, why did you NOT answer my question?
All Common, do you own NNVC stock?
NanoViricides, Inc. Finds FluCide(TM)-I Superior to Oseltamivir in Preliminary Animal Studies, Presents Data at the 7th Annual Targeted Nano-delivery Conference
A Company to Release Financials at the End of This Week
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 12:52 PM ET Oct 18, 2006
WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."
NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.
In other news, NanoViricides announced it is on target to release its financials by the end of this week.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc. Finds FluCide(TM)-I Superior to Oseltamivir in Preliminary Animal Studies, Presents Data at the 7th Annual Targeted Nano-delivery Conference
A Company to Release Financials at the End of This Week
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 12:52 PM ET Oct 18, 2006
WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."
NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.
In other news, NanoViricides announced it is on target to release its financials by the end of this week.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc. Finds FluCide(TM)-I Superior to Oseltamivir in Preliminary Animal Studies, Presents Data at the 7th Annual Targeted Nano-delivery Conference
A Company to Release Financials at the End of This Week
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 12:52 PM ET Oct 18, 2006
WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."
NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.
In other news, NanoViricides announced it is on target to release its financials by the end of this week.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
We are a "hot penny stock",lol-
Hot OTC Penny Stocks
Date: Tuesday, October 17, 2006
Derived from the 50 most active stocks priced under $1 listed on OTC
Symbol Company Name Volume Price High Low 52 High 52 Low
IPKL IPACKETS INTL INC 144,707,300 0.001 0.001 0.001 0.520 0.001
PLRS PLURISTEM LIFE SYSTEMS 115,576,500 0.028 0.030 0.021 0.153 0.016
SGID SILICON GRAPHICS 85,395,900 0.017 0.035 0.004 0.500 0.004
PAIM PEARL ASIAN MNG WY 80,181,400 0.001 0.001 0.001 0.010 0.001
SLWF SEAMLESS WI-FI INC 76,040,000 0.002 0.002 0.002 0.320 0.001
PTSH PTS INC 67,244,800 0.007 0.009 0.006 0.065 0.001
QBIT QUANTUM BIT INDUCTN 65,419,000 0.001 0.001 0.001 0.110 0.001
SSSU SILVER SCREEN STUDIOS 48,973,000 0.035 0.042 0.030 0.042 0.001
ETIM ETERNAL IMAGE INC 45,971,700 0.001 0.001 0.001 1.000 0.001
RSHN RUSHNET INC 45,215,700 0.001 0.002 0.001 0.068 0.001
PYPR PAYPRO INC 43,449,500 0.002 0.003 0.001 0.004 0.001
USXP UNIVERSAL EXPRESS INC 40,739,000 0.003 0.004 0.003 0.408 0.001
PBLS PHOENIX ASSOC LAND S 33,973,200 0.007 0.008 0.006 0.056 0.002
HISC HOMELAND INTEGRATED 31,365,200 0.005 0.006 0.004 0.100 0.002
GZFX GAMEZNFLIX INCORPORATED 28,254,200 0.004 0.004 0.004 0.182 0.003
NMCX NMC INC 24,240,800 0.023 0.024 0.021 0.125 0.009
IFQJ INFINITY ACQUISITION 22,907,500 0.001 0.004 0.001 0.250 0.001
GMSC GRAND ENT & MUSC 22,470,500 0.005 0.005 0.004 0.424 0.001
PHEI PHANTOM ENTERTAINMNT INC 19,909,600 0.005 0.008 0.005 0.465 0.001
ECFL ECARFLY INC 19,297,300 0.025 0.027 0.023 5.000 0.015
SEIH S3 INVESTMENT CO INC 17,535,000 0.001 0.001 0.001 0.018 0.001
SLJB SULJA BROS BUILDING 15,684,800 0.140 0.145 0.125 0.205 0.008
XKEM XECHEM INTERNATIONAL 15,643,500 0.024 0.025 0.023 0.495 0.001
UPDA UNIVERSAL PROP DEV & ACQ 15,193,800 0.074 0.083 0.070 0.845 0.006
BANY BANYAN CORPORATION OR 15,064,600 0.001 0.001 0.001 0.045 0.001
From RB board-
By: level59
16 Oct 2006, 06:13 PM EDT
Msg. 10658 of 10669
Jump to msg. #
Matt Patsky of Winslow Management was on Bloomberg TV this morning, mentioning UGNE among other names. I think this was the reason for the move today.
Here’s the transcript of the 5 min segment:
Oct. 16 (Bloomberg) -- Matthew Patsky, who manages about $200
million as a portfolio manager at Winslow Management Co., talks
with Bloomberg's Brian Sullivan from Boston about the performance
of environmentally sensitive stocks in the Winslow Green Growth
Fund, Patsky's recommendation of Zoltek Companies Inc., Fuel Tech
Inc. and Unigene Laboratories, Inc., and his strategy for small-
capitalization stocks.
(This is not a legal transcript. Bloomberg LP cannot
guarantee its accuracy.)
SULLIVAN: Well, today's market focus we've got Matt Patsky
on. He's a fund manager and managing director at Winslow
Management. He helps run their green growth fund, investing in
environmentally sensitive companies and it's been paying off. He
is outperforming the majority of his small cap fund manager peers.
And he joins us from Boston.
Matt, welcome back to the program. There's been a lot of talk
about going green and environmentally sensitive companies, and a
lot of the companies that you own in your portfolio have gone up.
How much of that do you think, though, is just a rush to sort of
embrace the environmental story, if you will, rather than
reflecting the fundamentals of these companies?
PATSKY: I have to think most of it is the fundamentals of the
companies. These are viable companies making money and I think
people are looking for, you know, profitable companies in addition
to the environmental story.
SULLIVAN: All right, and windmills we know that a lot of
hedge funds and private equity companies have been buying up these
wind farms, some of them rather quietly - but they've been doing
it. And there's a company that you like actually that helps make
the blades for the windmills.
PATSKY: Right. Zoltek is a manufacturer of carbon fiber,
which is one of the inputs into the blades for these wind
turbines. The wind turbines have been getting larger. The blades
have been getting larger and have been reaching beyond the
capacity of fiberglass, which was the material used before or
primarily. And now carbon fiber is the primary material being used
on the larger blades. Zoltek is a primary manufacturer and
supplier to Demasa and Vestas, which are very large wind turbine
makers in Europe.
SULLIVAN: OK. And the big knock on coal has been maybe the
environmental concerns about the emissions from coal plants, et
cetera.
PATSKY: Right.
SULLIVAN: There's another tech name that you like in the coal
space.
PATSKY: Yes, Fuel Tech is a company that we like which is
really a clean coal play. They have two technologies, one of which
allows for the cleaner burning of coal and one which allows for
the more efficient burning of coal, getting more output per ton of
coal and cleaner burning in the boiler and the actual furnace.
So Fuel Tech we think is a long-term play on the continuing
use of coal but cleaner in terms - and cleaner and more efficient
use of coal.
SULLIVAN: All right, so two of your picks are more in the
environmental space, if you will. You've also got a biotech name
if you will or call it a small pharmaceutical going against the
osteoporosis. And Fosamax, it's biggest competitor to Unigene's
product has had some issues with bone, I guess structural
problems, correct?
PATSKY: Correct.
SULLIVAN: And so Unigene will benefit?
PATSKY: Yes, Unigene is a - clearly a safer profile treatment
for osteoporosis than what we're seeing from Fosamax, which is the
biggest player in the osteoporosis market. What you are seeing -
we're seeing there is a side effect in using Fosamax which is bone
death, which is obviously very undesirable.
SULLIVAN: All right, now a lot of these names that we've
brought up and our viewers could see it, Matt, had some nice runs
here. I mean when you see a small cap stock with a hundred-plus
percent gains you think to yourself, you know, is it time to sell
a bit and take some profit?
PATSKY: Absolutely. There are certainly, you know, concerns
when you're seeing something run. But you have to remember that
oftentimes these are undiscovered, un-followed and there's a real
transition that's going on. That's - these companies have reached
inflection points where they're reaching profitability and there
is a lot of - and oftentimes a lot of upside in terms of the
leverage and the earnings.
An example, Fuel Tech could easily earn a dollar-plus when
you go out to 2008. The stock at 17 is not expensive when you
think about the kind of rapid growth and adoption we're seeing
with their fuel chem within the utility industry.
So I think there is a lot of upside in certainly the two that
have run, Zoltek and Fuel Tech and have done well. I think there's
still a lot of upside. These are two companies that have sort of
just broken into profitability.
Unigene we think will break into profitability. At that point
in time I think there's a lot of opportunity given - and people
aren't sure how much they can earn.
SULLIVAN: All right, Matthew Patsky is fund manager and
manager director at Winslow Management.
Matt, we appreciate your time this Monday morning, thank you
very much.
Press Release Source: CEL-SCI Corporation
CEL-SCI Will Hold Annual Meeting in Germany on November 17, 2006
Tuesday October 17, 9:00 am ET
VIENNA, Va., Oct. 17 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News), a drug development company with its lead cancer product cleared for a Phase III trial, announces that it will hold its annual meeting on Friday, November 17, 2006 at 12 PM at the Steigenberger Frankfurter Hof, Am Kaiserplatz, 60311 in Frankfurt am Main, Germany.
Maximilian de Clara, President of CEL-SCI Corporation said, "In addition to our U.S. listing, our stock is actively traded on five German stock exchanges where we also have many investors. We would like to give these investors the chance to meet with management and we feel that holding the meeting in Germany is a good way of achieving this goal."
Shareholders and investors who plan to attend the meeting are asked to let the Company know either by e-mail at cel-sci@cel-sci.com or by fax at U.S. (703) 506-9471.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine® is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
--------------------------------------------------------------------------------
Source: CEL-SCI Corporation
Hope the battery is overcharged,lol.
FW: Ya gotta love West Texas! zzzzzzzzzzzzzzzzzzap!
God Bless Bubba - City Councilman from Midland , TX
T. Bubba Bechtol, part time City Councilman from Midland , TX , was asked on a local live radio talk show the other day just what he thought of the allegations of torture of the Iraqi prisoners. His reply prompted his ejection from the studio, but to thunderous applause from the audience.
"If hooking up an Iraqi prisoner's scrotum to a car's battery cables will save one American GI's life, then I have just two things to say":
1. "Red is positive"
2. "Black is negative"
FW: Ya gotta love West Texas! zzzzzzzzzzzzzzzzzzap!
God Bless Bubba - City Councilman from Midland , TX
T. Bubba Bechtol, part time City Councilman from Midland , TX , was asked on a local live radio talk show the other day just what he thought of the allegations of torture of the Iraqi prisoners. His reply prompted his ejection from the studio, but to thunderous applause from the audience.
"If hooking up an Iraqi prisoner's scrotum to a car's battery cables will save one American GI's life, then I have just two things to say":
1. "Red is positive"
2. "Black is negative"
KCN, I think it is time for you to move to another board. TIA.